Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy

Dateline City: KENILWORTH, N.J. Results from C-EDGE CO-STAR Presented at The Liver Meeting® Show High Sustained Virologic Response After 12 Weeks of Treatment KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the company’s Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hep C Hepatitis C MSD NYSE:MRK Source Type: news

Related Links:

Authors: Karlis G, Mastora Z, Kakavas S, Pantikidi E, Kotanidou A PMID: 30024713 [PubMed - in process]
Source: Acta Gastro-Enterologica Belgica - Category: Gastroenterology Tags: Acta Gastroenterol Belg Source Type: research
This study was conducted on a total number of 59patients. These were subdivided into 25patients of hepatocellular carcinoma and 34 patients of chronic liver diseases (CLDs) with cirrhosis. All studied 59patients were associated with HCV infection. All patients were examined immunohistochemically to demonstrate the expression of MyeloperoxidaseResultsConcerning the expression of Myeloperoxidase in HCC and cirrhoticpatients; the study revealed that more MPO expression was found in HCC cases when compared with cirrhoticpatients (P –value
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
The drugs singled out for discounts include the flagging hepatitis C treatment Zepatier and six drugs that have lost their patent protection.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Prices (Fares, Fees and Rates) Drugs (Pharmaceuticals) Rebates and Refunds Merck & Company Inc Trump, Donald J Health and Human Services Department Source Type: news
An estimated 150 million people have chronic hepatitis C infection (HCV) [1], 3.5 million of whom live in the United States [2]. Half are thought to be unaware of their status since many experience no adverse symptoms of infection until late in progression [3], but 20% will develop cirrhosis, 10% end-stage liver disease or cancer, and approximately 3% will require a liver transplant or die [4].
Source: Patient Education and Counseling - Category: International Medicine & Public Health Authors: Source Type: research
HCV infections in the United States have increased significantly among young people during the past decade (Suryaprasad et al., 2014). Between 2002 and 2013, HCV infections in Massachusetts (MA) increased by 137% among those aged 15 –29, with more than 2,000 newly reported infections each year (MDPH, 2014). This increase has largely been attributable to injection drug use (MDPH, 2014). In recent years, new treatments have been developed for the hepatitis C virus (HCV) that could potentially be life saving for people who injec t drugs (PWID); however, uptake has been less than optimal.
Source: Drug and Alcohol Dependence - Category: Addiction Authors: Tags: Full length article Source Type: research
AbstractBackground/purposeIn Japan, there is a growing population of patients with chronic hepatitis C virus (HCV) infection who failed a direct-acting antiviral (DAA)-based regimen. In this Phase 3 study, we evaluated sofosbuvir –velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 HCV infection who previously received DAAs.MethodsPatients were randomized 1:1 to receive sofosbuvir –velpatasvir plus ribavirin for 12 or 24 weeks. Randomization was stratified by HCV genotype and presence of cirrhosis. The primary endpoint was sustained virologic response 12-week post-treatment (SVR12).Results...
Source: Hepatology International - Category: Infectious Diseases Source Type: research
The drugs singled out for discounts include the flagging hepatitis C treatment Zepatier and six drugs that have lost their patent protection.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Prices (Fares, Fees and Rates) Drugs (Pharmaceuticals) Rebates and Refunds Merck & Company Inc Trump, Donald J Health and Human Services Department Source Type: news
Merck&Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a little-used hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
ANN ARBOR, Mich. (CBS Local) – A disturbing new study declares that a growing number of young Americans are drinking themselves to death. The findings point to a skyrocketing increase in cirrhosis and liver cancer deaths over the last decade. According to the report published in the journal BMJ, deaths due to cirrhosis increased by 65 percent from 2009 to 2016. Deaths from liver cancer doubled (from more than 5,100 to nearly 11,100) during the same time period. Americans between 25-34 were found to be the largest group affected. Cirrhosis is a disease commonly caused by excessive drinking or ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Alcohol Drinking liver disease Local TV talkers Source Type: news
Sample: Which type of practitioner most often make the diagnosis of HCV: Gastro? GP? Hepatologist? Other?
Source: ConsultantLive - Category: Internal Medicine Authors: Tags: Hepatitis C Hepatitis C Quiz Source Type: news
More News: Clinical Trials | Hepatitis | Hepatitis C | Liver | Merck | Pharmaceuticals | Urology & Nephrology | Virology